Revision Anterior Cruciate Ligament Reconstruction in Adolescents
IRB Number: 10122
inactiveAugust 16, 2010
Institutional Review Board, Hospital for Special Surgery
The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.
For further information, see Understanding Clinical Trials/Research Studies.
Principal Investigator
Co-Investigators
- Keith R. Reinhardt, MD
- Sommer Hammoud, MD
- Andrea Bowers, MD
- David W. Altchek, MD
- Answorth A. Allen, MD
- Robert G. Marx, MD
- Andrew D. Pearle, MD
- Anil S. Ranawat, MD
- Anne M. Kelly, MD
- Beth E. Shubin Stein, MD Bryan T. Kelly, MD
- David M. Dines, MD
- Joshua S. Dines, MD
- Edward V. Craig, MD. MPH
- Howard AnthonyRose, MD
- Jo A. Hannafin, MD, PhD
- John D. MacGillivray, MD
- Michael J. Maynard, MD
- Riley J. Williams III, MD
- Russell F. Warren, MD
- Sabrina M. Strickland, MD
- Scott A. Rodeo, MD
- Stephen Fealy, MD
- Steve J. O’Brien, MD, MBA
- Struan H. Coleman, MD, MPH
- Thomas L. Wickiewicz, MD
Summary
Review of outcomes of revision ACL reconstruction in adolescent patients ages 12-18.
Inclusion/Exclusion Criteria
Review of outcomes of revision ACL reconstruction in adolescent patients ages 12-18.
Contact Information
Keith Reinhardt, MD
krr9009@gmail.com
646-678-4402